CDK2-IN-59 

CDK2-IN-59 is a CDK2 inhibitor with a IC₅₀ of 66.33 μM. CDK2-IN-59 stably interacts within the CDK2 active site and induces apoptosis in breast cancer cells. CDK2-IN-59 can be used for the research of breast cancer^[1].

CDK2-IN-59 (Compound 7d) (up to 500 μM) potently inhibits the proliferation of MDA-MB-231 breast cancer cells with an IC₅₀ of 5.16 μM^[1].
CDK2-IN-59 exhibits reduced cytotoxicity toward L929 murine fibroblast normal cells with an IC₅₀ of 59.10 μM and a selectivity index of 11.45 compared to MDA-MB-231 breast cancer cells^[1].
CDK2-IN-59 induces apoptosis in MDA-MB-231 breast cancer cells, driving 14.1% of cells into early apoptosis and 52.7% into late apoptosis^[1].
CDK2-IN-59 significantly inhibits CDK2/CyclinA2 enzymatic activity with an IC₅₀ of 66.33 μM^[1].
CDK2-IN-59 exhibits strong binding affinity for CDK2 (PDB ID: 4BCQ) with an MM/GBSA binding free energy of -53.28 kcal/mol^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

475.88

C₂₄H₁₈ClN₅O₄

COC1=CC=C(C2=CC(C3=CC=C(OC4=NC(N)=NC(Cl)=C4)C=C3)=C(C#N)C(N2)=O)C=C1OC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sutar NR, et al. New pyrimidine compounds as potent anti-breast cancer agents: synthesis, biological evaluation and computational studies. Bioorg Chem. 2026;178:109939.